

Flumequine, HRP conjugate

DAG1194

Lot. No. (See product label)

PRODUCT INFORMATION

Product overview	Flumequine, HRP conjugate
Antigen Description	The quinolones are antimicrobial agents that inhibit the activity of DNA gyrase and topoisomerase IV. The fluoroquinolones are divided into 2 groups, based on antimicrobial spectrum and pharmacology: The quinolones are active against a broad range of bacteria including Enterobacteriaceae, Streptococci, Chlamydia and Legionella. Older quinolones such as ciprofloxacin and norfloxacin have poor activity against streptococci and anaerobes. The quinolones are widely distributed to most body fluids and tissues. They are variably metabolised in the liver and excreted in the urine. Quinolones are used extensively in veterinary medicine and their use in food producing animals could result in potentially harmful concentrations in tissue, organs and milk. The potential risk is reduced by withdrawal of the drug for a fixed period before slaughter, although residual levels may remain.
Source	Antimicrobial Drugs
Conjugate	HRP
Form	concentrate
Characteristic	Each conjugate comprises antigen covalently bound to horseradish peroxidase and is suitable as a tracer in immunoassay development

PACKAGING

Storage	Can be stored at 2-8°C for up to 3 months and at -20°C for longer term storage.
----------------	---

BACKGROUND

Introduction	Flumequine is a synthetic chemotherapeutic antibiotic of the fluoroquinolone drug class used to treat bacterial infections. It is a first-generation fluoroquinolone antibacterial that has been removed from clinical use and is no longer being marketed. It kills bacteria by interfering with the enzymes that cause DNA to unwind and duplicate. Flumequine was used in veterinarian medicine for the treatment of enteric infections (all infections of the intestinal tract), as well as to treat cattle, swine, chickens, and fish, but only in a limited number of countries. It was occasionally used in France to treat urinary tract infections under the trade name Apurone. However this was a limited indication because only minimal serum levels were achieved.
Keywords	Flumequine; 7-fluoro-12-methyl-4-oxo-1-azatricyclo[7.3.1.0 ^{5,13}]trideca-2,5,7,9-tetraene-3-carboxylic acid; Apurone; R 802; Imequyl; Quinolone

REFERENCES

1. Department of Health and Human Services, Centers for Disease Control and Prevention, Quinolones and the Clinical Laboratory, <http://www.cdc.gov>. 2. The Merck Manual of Diagnosis and Therapy, <http://www.merck.com>.